Bioequivalence and comparative pharmacodynamics of insulin lispro 200U/mL relative to insulin lispro (Humalog®) 100U/mL

Clinical Pharmacology in Drug Development

Volumn 5, Issue 1, 2016, Pages 69-75

  de la Peña, Amparo ^a   Seger, Mary ^a   Soon, Danny ^b   Scott, Adam J ^a   Reddy, Shobha R ^a   Dobbins, Michael A ^a   Brown Augsburger, Patricia ^a   Linnebjerg, Helle ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bioequivalence; Diabetes mellitus; Insulin lispro; Pharmacodynamic; Pharmacokinetic

Indexed keywords

INSULIN LISPRO; ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; GLUCOSE CLAMP TECHNIQUE; MIDDLE AGED; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84954528476     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.221     Document Type: Article

References (16)

1. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000; 106:473-481.
2. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384:766-781.
3. Obesity Society. Your weight and diabetes. 2010. www.obesity.org/resources-for/your-weight-and-diabetes.htm.
4. Watson L, Wilson BP, Alsop J, Kumar S. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation? Diabetes Obes Metab. 2011; 13:823-831.
5. Aagren M, Luo W, Moes E. Heathcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization J Med Econom. 2010; 13(1)16-22.
6. Holleman F, Schmitt H, Rottiers R, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care. 1997; 20(12):1827-1832.
7. Bebakar WM, Lim-Abrahan MA, Jain AB, Seah D, Soewondo P. Safety and effectiveness of insulin aspart in type 2 diabetic patients: results from the ASEAN cohort of the A1chieve study. Diabetes Res Clin Pract. 2013;100(Suppl 1):S17-S23.
8. European Medicines Agency. Humalog Assessment Report #EMEA/H/C/000088/X/0125. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000088/WC500176634.pdf. Accessed March 19, 2015.
9. Eli Lilly and Company. Humalog KwikPen™ insulin lispro injection (rDNA origin): Instructions for use. http://pi.lilly.com/us/humalog-kwikpen-um.pdf. Accessed, March 19, 2015.
10. Dunn MF. Zinc-ligand interactions modulate assembly and stability of the insulin hexamer-a review. Biometals. 2005; 18(4):295-303.
11. Brange J, Langkjaer L. Chemical stability of insulin 3. Influence of excipients, formulation, and pH. Acta Pharm Nord. 1992; 4(3):149-158.
12. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. European Medicines Agency. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/ WC500070039. pdf. Accessed October 22, 2014.
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237:E214-E223.
14. Rave KM, Nosek L, de la Peña A. et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro Diabetes Care. 2005; 28(10)2400-2405.
15. EMD Millipore. LisPro Insulin RIA [LPI-16K]. http://www.emdmillipore.com/US/en/product/LisPro-Insulin-RIA, MM_NF-LPI-16K#anchor_TI. Accessed March 19, 2015.
16. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. May 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf. Accessed March 19, 2015.